Loading company
Syndax Pharmaceuticals Inc
SNDX · Nasdaq · ·
Next earnings: November 2, 2026
$18.24+2.1%Sep 29 close
- 1M
- -6.7%
- 6M
- -18.9%
- 1Y
- +18.5%
- 5Y
- -7.7%
SNDX · Nasdaq · ·
Next earnings: November 2, 2026
$18.24+2.1%Sep 29 close
Syndax Pharmaceuticals Inc is scheduled to report next on November 2, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $72.8M | $38M | +91.76% |
| Profit | -$49.4M | -$71.8M | +31.29% |
| Profit per share | -$0.55 | -$0.83 | +33.73% |
| Free Cash Flow | -$15.1M | -$12.8M | -17.96% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We delivered another quarter of strong commercial results, with both our medicines now annualizing at well over $200 million each and positioned for further growth,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj ® (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Syndax Pharmaceuticals Inc’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Syndax Pharmaceuticals Inc has no earnings call transcript available.